Also, primary AML samples were evaluated when grown on bone marrow stromal cells and the strongest decreases in cell viability upon co-inhibition of SDH and MCT1 were seen in primary FLT3-ITD+ AMLs, whereby healthy control CB-derived CD34+ cells were not sensitive to this combination of inhibitors (Fig. 5d). This evidence concerns the gene SLC16A1 and acute myeloid leukemia.